97 related articles for article (PubMed ID: 17302283)
1. [Perspective for imaging of tumor metabolism].
Kubota K; Yukihiro M; Ito K
Nihon Rinsho; 2007 Feb; 65(2):352-6. PubMed ID: 17302283
[TBL] [Abstract][Full Text] [Related]
2. Imaging of tumor glucose utilization with positron emission tomography.
Buerkle A; Weber WA
Cancer Metastasis Rev; 2008 Dec; 27(4):545-54. PubMed ID: 18523732
[TBL] [Abstract][Full Text] [Related]
3. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging.
Kumar R; Dhanpathi H; Basu S; Rubello D; Fanti S; Alavi A
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):50-65. PubMed ID: 18235421
[TBL] [Abstract][Full Text] [Related]
4. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
6. Metabolic PET Imaging in Oncology.
Sai KKS; Zachar Z; Bingham PM; Mintz A
AJR Am J Roentgenol; 2017 Aug; 209(2):270-276. PubMed ID: 28463521
[TBL] [Abstract][Full Text] [Related]
7. Positron-emission tomographic imaging of cancer: glucose metabolism and beyond.
Mankoff DA; Bellon JR
Semin Radiat Oncol; 2001 Jan; 11(1):16-27. PubMed ID: 11146039
[TBL] [Abstract][Full Text] [Related]
8. Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies.
Fukuchi K; Ohta H; Matsumura K; Ishida Y
Br J Radiol; 2007 Jan; 80(949):3-11. PubMed ID: 17005513
[TBL] [Abstract][Full Text] [Related]
9. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
10. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
11. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
[TBL] [Abstract][Full Text] [Related]
12. Is 18F-FDG PET/CT useful for imaging and management of patients with suspected occult recurrence of cancer?
Israel O; Mor M; Guralnik L; Hermoni N; Gaitini D; Bar-Shalom R; Keidar Z; Epelbaum R
J Nucl Med; 2004 Dec; 45(12):2045-51. PubMed ID: 15585480
[TBL] [Abstract][Full Text] [Related]
13. [Clinical usefulness of FDG-PET in oncology].
Sasaki M
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
[TBL] [Abstract][Full Text] [Related]
14. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
15. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF
Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185
[TBL] [Abstract][Full Text] [Related]
17. PET/CT imaging in cancer: current applications and future directions.
Farwell MD; Pryma DA; Mankoff DA
Cancer; 2014 Nov; 120(22):3433-45. PubMed ID: 24947987
[TBL] [Abstract][Full Text] [Related]
18. [New functional imaging technique "positron emission tomography"].
Tamaki N
Hokkaido Igaku Zasshi; 1998 Mar; 73(2):101-4. PubMed ID: 9612703
[TBL] [Abstract][Full Text] [Related]
19. Molecular imaging agents for clinical positron emission tomography in oncology other than fluorodeoxyglucose (FDG): applications, limitations and potential.
Mercer JR
J Pharm Pharm Sci; 2007; 10(2):180-202. PubMed ID: 17706177
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG imaging: pitfalls and artifacts.
Abouzied MM; Crawford ES; Nabi HA
J Nucl Med Technol; 2005 Sep; 33(3):145-55; quiz 162-3. PubMed ID: 16145222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
